Cytosorbents Corporation
CTSO
$0.79
$0.045.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -1.37% | 10.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.37% | 10.20% | |||
| Cost of Revenue | 0.57% | 11.25% | |||
| Gross Profit | -2.17% | 9.77% | |||
| SG&A Expenses | -8.26% | 8.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.20% | 4.90% | |||
| Operating Income | 26.36% | 7.00% | |||
| Income Before Tax | -283.41% | 231.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -262.81% | 231.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -262.81% | 231.70% | |||
| EBIT | 26.36% | 7.00% | |||
| EBITDA | 28.42% | 8.76% | |||
| EPS Basic | -262.38% | 227.98% | |||
| Normalized Basic EPS | -273.20% | 227.63% | |||
| EPS Diluted | -268.33% | 223.46% | |||
| Normalized Diluted EPS | -285.64% | 219.08% | |||
| Average Basic Shares Outstanding | 0.23% | 3.09% | |||
| Average Diluted Shares Outstanding | -6.57% | 10.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||